DrugPatentWatch Database Preview
ANGIOMAX Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Angiomax patents expire, and when can generic versions of Angiomax launch?
Angiomax is a drug marketed by Sandoz Inc and Maia Pharms Inc and is included in two NDAs. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in ANGIOMAX is bivalirudin. There are fourteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
US ANDA Litigation and Generic Entry Outlook for Angiomax
A generic version of ANGIOMAX was approved as bivalirudin by HOSPIRA INC on July 14th, 2015.
Summary for ANGIOMAX
Recent Clinical Trials for ANGIOMAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pacific University | Phase 4 |
| Legacy Health System | Phase 4 |
| Qian Gong | Phase 2 |
Pharmacology for ANGIOMAX
| Drug Class | Anti-coagulant Direct Thrombin Inhibitor |
| Mechanism of Action | Thrombin Inhibitors |
Paragraph IV (Patent) Challenges for ANGIOMAX
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| ANGIOMAX | INJECTABLE;INTRAVENOUS | bivalirudin | 020873 | 2009-09-01 |
US Patents and Regulatory Information for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||
| Maia Pharms Inc | ANGIOMAX RTU | bivalirudin | SOLUTION;INTRAVENOUS | 211215-001 | Jul 25, 2019 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ANGIOMAX
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 652125 | Start Trial |
| South Korea | 100259759 | Start Trial |
| World Intellectual Property Organization (WIPO) | 9102750 | Start Trial |
| Canada | 2065150 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for ANGIOMAX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0489070 | C00489070/01 | Switzerland | Start Trial | FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH |
| 0489070 | SPC/GB04/035 | United Kingdom | Start Trial | PRODUCT NAME: H-(D-PHE)-PRO-ARG-PRO-(GLY)4-ASN-GLY-ASP-PHE-GLU-GLU-ILE-PRO-GLU-GLU-TYR-LEU-OH, OPTIONALLY IN THE FORM OF ITS PHARMACEUTICALLY ACCEPTABLE SALT (BIVALIRUDIN); REGISTERED: UK EU/1/04/289/001 20040920 |
| 0489070 | CA 2004 00032 | Denmark | Start Trial | |
| 0489070 | 300162 | Netherlands | Start Trial | PRODUCT NAME: BIVALIRUDINE; FIRST REGISTRATION,DATE: EU/1/04/289/001, 20040920 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
